Home > Insider Trading > Filing (0000919574-23-003408)

Filing Details

Accession Number:: 0000919574-23-003408
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-05-18 20:31:35
Reporting Period:: 2023-05-16

Accepted Time:: 2023-05-18 20:31:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
834365	Biolife Solutions Inc	BLFS	Electromedical & Electrotherapeutic Apparatus (3845)	943076866

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1534260	Casdin Partners Gp, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No
1534261	Casdin Capital, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No
1534264	Eli Casdin	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No
1534265	Casdin Partners Master Fund, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $.001 Per Share	Acquisiton	2023-05-16	15,000	$20.19	15,000	No	4	P	Indirect	See footnote
Common Stock, Par Value $.001 Per Share	Acquisiton	2023-05-17	30,027	$21.30	45,027	No	4	P	Indirect	See footnote
Common Stock, Par Value $.001 Per Share	Acquisiton	2023-05-18	30,000	$21.76	75,027	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $.001 Per Share	7,571,535	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $20.1643 to $20.2385. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The securities are owned directly by a client of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such client; (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of such client, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $20.98 to $21.8582. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.